Clinical Trials
4
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- HitGen Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT06781567
- Locations
- 🇨🇳
Shanghai Oriental Hospital, Shanghai, Shanghai, China
A Study of HG381 Administered to Patients With Advanced Solid Tumors
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- HitGen Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT04998422
- Locations
- 🇨🇳
HitGen Inc., Chengdu, Sichuan, China
Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- HitGen Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT04977167
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Beijing, China
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
Phase 1
Terminated
- Conditions
- Multiple MyelomaRelapsed and Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- HitGen Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03710915
- Locations
- 🇨🇳
HitGen Inc, Chengdu, Sichuan, China
News
No news found